More than 20 trials around the world are testing Kaletra as a
COVID-19 treatment or post-exposure prophylaxis.
Russia's Health Ministry recommended it as a possible treatment for
COVID-19 at the end of January after reports from China that it was
beneficial, but later added that its efficacy was uncertain.
That did not deter speculators who bet that shortages of the drug,
also produced as a generic in Russia under the name Kalidavir, might
arise as the coronavirus spread.
"Three months ago, people were buying Kaletra from us without much
enthusiasm for 900 roubles ($12) a box," one online trader of HIV
drugs said.
"Now, anticipating (supply) interruptions, people are buying between
100 and 700 boxes from us, at 3,800 roubles a box. Mainly, people
are buying (Kaletra) with the aim of reselling it for a very high
price."
Resellers can get 7,000-8,000 roubles per box, the trader said - and
that frenzy is worrying some HIV-positive people.
The number of new coronavirus cases in Russia began rising sharply
this month, and on Monday it reported a daily rise of 4,268 cases,
bringing the nationwide tally to 47,121.
Kaletra, as with many other prescription-only HIV treatments in
Russia, is purchased in bulk by the government and distributed to
registered HIV patients for free.
But interruptions in supplies of these drugs are not uncommon, so
many top up their stocks privately, from pharmacies. People who do
not have a Russian passport and others who prefer to stay out of the
official system for various reasons also rely on private supplies.
'120 CALLS A DAY'
The director of H-Clinic in St. Petersburg, which specialises in
infectious diseases and keeps a stock to cover those needs, said his
pharmacy had been flooded with calls in recent weeks from worried
HIV patients.
"We have a van coming from the pharmaceutical company, and
everything in it has already been claimed in orders," Andrei
Skvortsov said. "There were up to 120 calls a day."
The pharmacy's supplies of the generic, Kalidavir, were stable, he
said, but the distributor of Kaletra had told him the delivery would
be the pharmacy's last because of the need to redirect it for state
tenders.
The Health Ministry did not respond to questions about the drug's
resale online or possible shortages.
It first instructed doctors to use Kaletra's combined components,
lopinavir and ritonavir, to treat COVID-19 on Jan. 29, based on
studies of the treatment of other coronaviruses, such as Severe
Acute Respiratory Syndrome (SARS).
Produced in Russia by R-Pharm under a deal with the U.S. drug maker
and patent-holder AbbVie Inc <ABBV.N>, Kaletra is supplied in
smaller quantities to some pharmacies and AIDS clinics.
[to top of second column] |
Just 34 packs were sold by such pharmacies in March last year, compared to over
1,500 in March 2020, market research firm Alpharm said.
One HIV activist in central Russia said speculators were trying to buy Kaletra
from HIV patients, for 3,000 roubles a box.
The activist, who asked to share only his first name, Alexei, runs a 'back-up
medicine cabinet' together with a network of patients across 20 cities,
stockpiling leftover drugs to distribute them to those in need when shortages
appear.
BLACK MARKET
"Messages and calls started coming in from people saying they were ready to
purchase these medicines," Alexei said.
"They are resellers and middlemen ... They are ready to buy everything, down to
the last box. We tell them to shove off."
R-Pharm chief executive Alexei Repik said for the first time instances were
being seen of Kaletra being sold illegally in pharmacies without a prescription.
"It used not to feature at all, because ... the medicine was previously only
needed by HIV patients," he said.
Repik said police had notified R-Pharm at least twice of seizures of illegally
obtained Kaletra.
R-Pharm assists police in tracing the provenance of drugs being sold illegally,
he said, because black market sales of any drug meant patients who truly needed
it were losing out.
Kaletra's side-effects most commonly include stomach upset and nausea, but it
can also lead to liver and heart rhythm problems, meaning it could be dangerous
to self-prescribe, he said.
But Repik did not expect shortages, because R-Pharm was boosting production to
cope with expected demand from doctors prescribing Kaletra for coronavirus as
well as HIV.
"But of course no one can predict the full scale of the epidemic," he added.
Chinese doctors in Wuhan, where the new coronavirus originated, described the
drug as beneficial last week although another study questioned its
effectiveness.
Kaletra stops the HIV virus growing and replicating. Repik said it had been
recommended for the new coronavirus based on past experience with other
coronaviruses and preliminary data.
"(But) it is important to understand that, for now, 100% proven antiviral
medicines - medicines that directly attack the (new) coronavirus specifically -
they don't exist, because studies are still ongoing."
(Additional reporting by Polina Nikolskaya; Writing by Polina Ivanova; Editing
by Andrew Osborn and Kevin Liffey)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |